Background: Mitral regurgitation (MR) is a frequent consequence of mitral valve prolapse (MVP). However, the echocardiographic grading of MR is challenging, and the recommended grading parameters have several limitations. The authors developed a novel echocardiographic parameter to grade MR, the average pixel intensity (API) method, on the basis of pixel intensity analysis of the continuous-wave Doppler signal.
to the clinical validation of the API method. Also, follow-up data of patients not experiencing clinical events are reported to assess the value of the API method for echocardiographic surveillance of MVP-MR.
METHODS

Patient Selection and Transthoracic Echocardiography
Transthoracic echocardiography was performed in 149 consecutive MVP-MR patients at Gent University Hospital (all performed using a Vivid E9 XDclear echocardiographic machine and an M5Sc-D probe; GE Healthcare, Waukesha, WI). Patients were prospectively included between 2014 and 2018. In case of follow-up echocardiography, there was a minimum time interval of 1 year between the two acquisitions. Mitral valve prolapse (MVP) was defined as an abnormal systolic displacement of one or both mitral leaflets into the left atrium (displacement > 2 mm above the annular plane in the parasternal long-axis view). 4, 5 Echocardiographic exclusion criteria were identical to those previously described. 15 The study was approved by the local ethics committee.
Echocardiographic Assessment of MR with the API Method Machine Settings
The API method was applied as previously reported, 12, 15 and we extensively describe this method and all its practical steps in holosystolic and nonholosystolic MVP-MR in the online supplemental API guide.
The power and transmission frequency of the CW Doppler system were fixed at 0 dB and 2 MHz, respectively. Through trial and error and before patient enrollment, we found that the CW Doppler gain level was optimal at 6 dB, and this gain level was eventually fixed and used for all patients. Notably, at this gain level, oversaturation or undersaturation of the CW Doppler signal intensity was avoided irrespective of MR severity (i.e., keeping the grayscale intensity histograms always >0 arbitrary units [au; the unit of API; absolute black] and always <255 au [absolute white]). Also, although the intensity of the CW Doppler signal (and thus MR severity) demonstrates a nonlinear sigmoidal function, the vast majority of patients (analyzed at 6dB) are within the linear part of the sigmoidal curve. Finally, because the gain level is vendor and machine specific, we recommend using only the Vivid 9 XDClear or Vivid E95 system with the M5Sc-D probe for assessing API. For more detailed information on gain and other technical issues on the API method, we refer the reader to the extensive online supplemental API guide.
Calculation of API
Following the acquisition of the CW Doppler signal, the CW envelopes of MVP-MR are manually traced offline, starting from the mitral closure signal to the end of the CW envelope. In nonholosystolic jets, tracing starts from the mitral valve closure signal, and an imaginary holosystolic envelope is traced around the partially absent parabole (Figure 1 ). These traced areas are then converted into a grayscale, and the API value is calculated using custommade software.
All echocardiographic acquisitions were performed by a single operator (F.T.), blinded to the patient's clinical status and to the initial echocardiographic findings in the second echocardiographic study. API analyses were performed by one operator (V.K.), blinded to the clinical and echocardiographic characteristics of the patients.
Quantitative MR Grading with PISA-Based Methods and VCW VCW, PISA-EROA, and PISA-RV were carefully assessed as previously reported and according to consensus recommendations. 4, 5, 12 To determine PISA-RV, PISA-EROA is multiplied by the time-velocity integral (TVI) of the CW Doppler MR velocity profile. To obtaining the TVI value, the tracing of the CW envelope was limited to the duration of MR, thus at the distinct CW envelope border. 15, 16 
Assessment of Clinical Outcomes
Clinical outcomes were assessed using patient records from our and other institutions. If no information was available, patients and/or their general practitioners were contacted. The main outcome was major adverse cardiac events (MACE), including cardiovascular mortality, mitral valve surgery, percutaneous mitral intervention, and heart failure hospitalization. The decision for surgery was guidelinebased (class I or IIa indication; symptoms or asymptomatic patients with left ventricular [LV] dysfunction [LV end-systolic diameter > 45 mm and/or ejection fraction < 60% and/or right ventricular systolic pressure (RVSP) > 50 mm Hg] 3, 17 ) and was made by a multidisciplinary team that followed a multi-integrative approach considering multiple echocardiographic and clinical variables. Importantly, the clinical judgment of the treating physician and surgical team was blinded to the patients' API values.
Statistical Analysis
Continuous variables are expressed as mean 6 SD (or median with interquartile range for non-normal distributions) and dichotomous variables as percentages. Normality of data distribution was tested using the Shapiro-Wilk test. Student's t test or the Mann-Whitney U test (for continuous variables) and the c 2 test (for dichotomous variables) were used to evaluate significant group differences. For repeated measures, the paired t test, Wilcoxon test, and McNemar test were used, respectively. All statistical analyses were performed using SPSS Statistics version 24 (IBM, Armonk, NY), including plotting of receiver operating characteristic (ROC) curves and Kaplan-Meier graphs. We used the Henley-McNeal test for differences between area under the curve (AUC). The Cochran-Mantel-Haenszel test was used for calculation of odds ratios, and the Youden index was used to determine optimal cutoff points on ROC curves. P values < .05 were considered statistically significant. Table 1 shows the clinical and echocardiographic characteristics of the patient population (N = 136), according to occurrence of events (MACEs). Baseline characteristics of the cohort stratified according to API tertiles are shown in Supplemental  Table 1 .
RESULTS
Baseline Characteristics
The number of subjects in whom the various echocardiographic parameters could be obtained was similar to that in prior reports 15 : 90% for the API method (136 of 149 patients, 136 patients included for outcome analysis), which was significantly higher than for PISA-based methods (106 of 149 patients [71%]) and VCW (103 of 149 patients [69%]; P < .001).
Clinical Outcome
During a median follow-up period of 17 months (interquartile range, 5-24 months), 48 patients (35%) experienced clinical events: four patients (3%) died of noncardiac causes, whereas 44 patients (32%) had MACEs (cardiovascular mortality [4%], mitral valve surgery [27%], percutaneous mitral intervention [2%], heart failure hospitalization [2%]). In the cohort of patients requiring mitral valve surgery, indications for surgery were overt dyspnea (class I indication; 87%) or one or more echocardiographic measures showing hemodynamic and/ or structural cardiac repercussions such as LV dilation, left atrial (LA) dilation, or high RVSP (class IIa indication; 13%). 3, 17 As can be appreciated from Table 1 , the API value was significantly higher in the event group. Similarly, other direct measures, such as PISAbased methods and VCW, were higher in the event group. Regarding indirect measures of hemodynamic severity, such as ventricular and atrial dimensions and RVSP, all were higher in the event group, but not all differences were statistically significant. In the event group, there were significantly more holosystolic than nonholosystolic MVP-MR jets and also more frequently eccentric jets. New York Heart Association functional class was significantly higher in the event group.
Kaplan-Meier graphs were plotted on the basis of MACE-free survival during the follow-up period. For API, using the 111 au cutoff value, the Cochran-Mantel-Haenszel test was highly significant for event prediction (odds ratio, 26.4; 95% CI, 10.2-68.3; P < .001). After stratification of API according to tertiles, this remained highly Figure 1 Methodology of the API method. The left panel shows the acquisition of the CW Doppler signal in MVP-MR, the cursor well aligned with the MR jet direction. Next, the CW Doppler envelope is manually traced by the operator, as shown in the upper middle panel. As shown in the middle panels, in holosystolic MVP-MR, this tracing is straightforward, as the contours of the distinct CW envelope are followed. In nonholosystolic MVP-MR, tracing starts from the mitral valve closure signal, and an imaginary holosystolic envelope is traced around the partially absent CW parabole. This tracing approach is fundamental to the API concept, as API considers the entire systolic cycle, irrespective of MR flow (rates). The upper right panel demonstrates the digital output with the mean API value (green dotted line), the maximal and minimal pixel intensities over time in red and blue dotted lines, respectively. Below, a series of cases that cover the range of degrees of MR in this MVP study population is shown, with their respective API values.
HIGHLIGHTS
The API method is a novel echo parameter for grading mitral regurgitation. The applicability of the API method is superior to conventional grading methods. The API method is a significant predictor for clinical outcome. significant (tertile 2 vs tertile 1: odds ratio, 8.4; 95% CI, 1.8-40.3; P = .002; tertile 3 vs tertile 1: odds ratio, 67.5; 95% CI, 14.0-325.2; P < .001; Figure 2 ). Similarly, PISA-EROA, PISA-RV, and VCW were predictive for events using their recommended cutoffs (P < .001 for all). When comparing the API graphs with other direct parameters as shown in Figure 3 , the upper lines in Figures 3A (PISA-EROA), 3B (PISA-RV), and 3C (VCW) reflect the superior negative predictive value of the API method compared with the other parameters, which implies that patients with API values below the threshold of 111 au will be less likely to develop events when predicted using the API method. Finally, in the present study, both the 2012 and 2017 European Society of Cardiology guidelines 3, 17 for valve disease were considered for decision making but did not affect the results or outcome data.
API Severity Cutoffs in MVP-MR
ROC curves were constructed on the basis of the occurrence of MACE to determine an optimal cutoff for the API method ( Figure 4 ). An API value of 111 au was found to have the highest Youden index (0.69), with sensitivity of 86% and specificity of 83%. Correcting API for body surface area, height, LV enddiastolic volume, or LV end-systolic volume did not improve the AUC (data not shown). Constructing ROC curves for PISA-EROA and PISA-RV resulted in similar AUCs (no statistical difference), implying similar predictive value of methods. However, when taking into account the cutoffs for qualifying severe MVP-MR (0.4 cm 2 and 60 mL, respectively), the sensitivity of the PISA method was much lower than that of the API method (54% and 56%, respectively), but with high specificity (96% and (23) LA diameter, mm 40 (7.4) 46 (7) .001 ‡ 42 (8) EF, % 58 (9) 58 (7) .885 ‡ 58 (9) RVSP, mm Hg 30 (9) 91%). Guided by the Youden index, we found the optimal cutoff for PISA-EROA at 0.3 cm 2 (Youden index = 0.57, sensitivity 72%, specificity 83%) and for PISA-RV at 36 mL (Youden index = 0.57, sensitivity 80%, specificity 78%). These ''corrected'' PISA-EROA and PISA-RV cutoffs correspond to the API cutoff of 111 au and are comparable with the PISA-EROA and PISA-RV cutoffs in a very recent study. 18 Regarding VCW, sensitivity of 44% and specificity of 94% were found at the recommended cutoff of 7 mm, but when using the Youden approach, we found sensitivity of 80% and specificity of 78% (cutoff value 5.5 mm; Figure 4 ). ROC curves were also made for indirect measures of hemodynamic severity. However, only moderate AUC values were found for end-diastolic volume (0.65), end-systolic volume (0.62), enddiastolic diameter (0.71), and end-systolic diameter (0.60). RVSP was more powerful in predicting MACEs (AUC = 0.86), with an optimal cutoff point of 34 mm Hg, as was LA volume index (AUC = 0.81, best cutoff 81 mL).
Follow-Up of Surgically Treated Patients
In patients who underwent surgery, we reassessed clinical and echocardiographic outcomes after a median follow-up time of 19 months. We found significant reductions of LV end-diastolic diameter, indexed LA volume, RVSP, and symptoms (P < .001; data not shown). This provides additional clinical and biologic evidence for the validity of the API method.
Follow-Up of Nonevent Patients
Among the 92 patients who did not experience clinical events, 49 patients underwent follow-up echocardiographic examinations, which were performed after a median time interval of 16 months (minimum interval of 12 months after initial evaluation; range, 12-48 months; Table 2 ). Patients in this cohort mainly had nonholosystolic jets (66%), and during this interval, only a few (4%) evolved to holosystolic jets. Baseline values indicate that this cohort had mainly nonsevere MVP-MR, as direct and indirect parameters of MR severity fell below established severity cutoffs. At follow-up echocardiography, API increased from 80 to 86 au (P = .042), which was borderline significant and is attributed to a few outliers (n = 3, not shown). There were also mild but nonsignificant increases in VCW, PISA-EROA, and PISA-RV. When considering the several indirect parameters of MR severity, there was an overall nonsignificant trend of increases for all measurements, along with the direct parameters. Only ejection fraction remained similar to the first measurement. Importantly, the API method could be reapplied successfully in all patients at follow-up, whereas for the PISAbased methods and VCW, in only 60% and 62% of patients, Figure 2 Kaplan-Meier graphs on the basis of API tertiles. Kaplan-Meier graphs were plotted for the API method on the basis of MACE-free survival during the follow-up period. After stratification of API values according to tertiles, there was a significant difference in outcome between the three groups (tertile 2 vs tertile 1: odds ratio, 8.4; 95% CI, 1.8-40.3; P = .002; tertile 3 vs tertile 1: odds ratio, 67.5; 95% CI, 14.0-325.2; P < .001).
Figure 3
Comparison of the API method with PISA-based methods and VCW. Kaplan-Meier graphs were plotted to compare the event prediction of the API method with the PISA to calculate the EROA and RV, and VCW, after dichotomization of the parameters on the basis of their cutoffs (respectively, 111 au, 0.4 cm 2 , 60 mL, and 7 mm). The black lines illustrate the slightly better (A) or similar (B, C) positive predictive value of PISA-based methods and VCW compared with the API method. However, the blue lines consistently show the better negative predictive value of the API method over the other parameters (panels A, B, and C).
respectively, these measurements could be performed successfully at both echocardiographic examinations.
DISCUSSION
In the present study, we show that the API method is a useful echocardiographic grading method for clinical event prediction in MVP-MR. Previously, we also showed that the API method has higher feasibility and reproducibility (inter-and intraobserver agreement being 0.98 and 0.97, respectively) than conventional MR grading methods. 12, 15 This clinical validation, along with its excellent feasibility and reproducibility, makes the API method a valuable tool for assessment and follow-up of MVP-MR in daily clinical practice.
Importantly, our API data corroborate previous studies showing that quantification of MVP-MR is valuable for event prediction and follow-up of patients with MVP-MR. 8 Compared with the proposed API cutoff of 111 au, indirect measures of hemodynamic MVP-MR severity such as LV end-systolic diameter, LV end-diastolic diameter, and ejection fraction have suboptimal associations with outcome, whereas RVSP and LA volume had good correlations. Moreover, compared with the PISA-EROA 0.4 cm 2 and API 111 au cutoffs, all the indirect hemodynamic and dimensional cutoffs (including the presence of an eccentric, holosystolic jet) lack specificity. Finally, the presence of nonholosystolic MVP-MR has strong negative predictive value in terms of outcome, as has been reported. 15, 16 Timing for Surgery Surgical or percutaneous intervention is recommended in patients with MVP-MR who present with symptoms. Yet 40% and 37% of our patients with symptoms (and thus surgical indications) had PISA-EROA and PISA-RV values below the MR severity cutoffs of 0.4 cm 2 and 60 mL, respectively, indicating that these cutoff values do not correlate well with symptom status in MVP-MR. Moreover, in the cohort of patients in whom PISA was not feasible, five events occurred, which actually further reduces the sensitivity of the PISA method. The proposed API cutoff of 111 au had much higher sensitivity compared with the PISA-EROA 0.4-cm 2 threshold. However, when extrapolating this 111 au API cutoff to determine PISA-based cut-offs, an EROA of 0.3 cm 2 and an RV of 36 mL were obtained. Interestingly, this API-guided PISA-EROA cutoff of 0.3 cm 2 is in accordance with a recent report showing that excess mortality in MVP-MR occurs independently at EROA values far below 0.4 cm 2 , indicating that this traditional 0.4-cm 2 cut-off seems suboptimal. 18 It should be acknowledged that our prospective, consecutive population of patients with MVP-MR had a relatively high prevalence of subjects with severe MVP-MR who underwent MV intervention, probably because our institution is a referral center for advanced cases. This relative high prevalence may also partly explain the strength of the relationship of API and events.
Surgical intervention in asymptomatic patients with MVP-MR remains subject to debate among opinion leaders. However, in the major studies comparing outcomes with early intervention versus conservative treatment strategies, different methods of MR severity assessment have been used. Moreover, different degrees of MR severity might have been compared when considering the LV dimensions in their cohorts. 19, 20 Because grading issues blur the conclusions in this important topic, the need for reproducible and accurate grading of MVP-MR is again emphasized.
What can the API method add in this controversial field? Apart from its current clinical validation, its effectiveness (fast and easy applicability in real-world consecutive patients), and reproducibility, the API method avoids potential pitfalls encountered in MVP-MR grading, especially in the nonholosystolic cohort, in which PISA-EROA assessment and TVI tracing can be challenging, as previously shown by our group and by others. 15, 16 Apart from the nonholosystolic pattern of the CW Doppler signal being a good qualitative marker of nonsevere MR in general, the API method may provide additional prognostic value in this nonholosystolic cohort, as API inherently considers MR duration, similar to PISA- Figure 4 ROC curves were constructed on the basis of the occurrence of MACEs to determine an optimal cutoff for the API method, which was 111 au. For the PISA to calculate the EROA and RV, and VCW, the recommended cutoff values are indicated by the red dots on their respective ROC curves (conventional cutoffs). In the ROC curves below (Youden index-based cutoffs), we show the respective sensitivity and specificity for the cutoffs deduced from the Youden index approach.
RV but not PISA-EROA or VCW, which are single-frame measures. We illustrate this in Figure 5 .
The follow-up data in nonoperated patients comprised >60% nonholosystolic MVP-MR jets. Notably, after a median follow-up period of 16 months, most of the patients with nonholosystolic MVP-MR remained asymptomatic, while having no or minor increases in API values, indicating a more benign course of nonholosystolic MVP-MR. In fact, no patients in this cohort evolved to API values > 111 au. These follow-up data, in congruence with the evolving average values of the PISA method in this cohort, strengthen the robustness and clinical validity of the API method.
CMR: The Reference Method for Assessing MR Severity in MVP?
No gold standard exists for grading MR severity, however, CMR has been suggested to be the ''reference method'' for grading MR severity. 21, 22 In a recent study, 10 CMR was claimed to be the optimal tool for event prediction and surgical decision in patients with MVP-MR, outperforming echocardiographic assessment. Although in general, echocardiography performed well in predicting outcomes in that study, discordance between echocardiographic and CMR grading occurred in patients with MVP-MR with multiple jets and in the cohort in which echocardiography overestimated MVP-MR severity compared with CMR. 10 In the latter cohort, MR was classified as severe by echocardiography, despite the presence of 87% nonholosystolic jets and nondilated left atria or ventricles. 10 Also, when considering MR hydraulics in this nonholosystolic cohort and deriving the TVI value from the reported EROA and RV values, a high TVI value of 173 cm is obtained, which is similar to the TVI values deduced from the holosystolic MVP-MR patients (and thus overestimating RV calculation). 10 We and others have shown that TVI values are much lower in nonholosystolic MVP-MR and that nonholosystolic MVP-MR is rarely severe, 15, 16 as also illustrated by the LV enddiastolic values in these patients. 10, 15, 16 This again emphasizes that careful echocardiographic grading in nonholosystolic MVP is crucial, and it points to the added value of the API method in MVP-MR, as the API approach readily reveals the nonholosystolic nature and avoids complex calculations or geometric assumptions (see also Figure 5 ). We believe that CMR could be useful as a second line in MVP with large multiple jets, in case of suboptimal imaging or when clear discrepancy occurs between echocardiographic MR grading and LV and LA dimensions. New algorithms on the integration of CMR have been proposed. 23 
Applying API in MVP-MR: Considerations and Limitations
The API method may improve MR grading, but it should be noted that the present results apply only to MVP cases of MR. Also, the API method does not replace the multiparametric approach recommended by the American Society of Echocardiography and European Association of Cardiovascular Imaging to assess MR, but the API method could be valuable to assist in the determination of MR severity in MVP cases in which discrepancies in the individual components exist. Apart from the potential advantages of the API method, some important practical issues are to be considered. Obviously, ''suboptimal'' imaging quality may limit the application of API, and future research will focus on an algorithm that corrects for Doppler signal attenuation. Currently, we do not have a reli-able ''quality control,'' but several breath-holding attempts are encouraged to obtain the most intense CW Doppler signal for API analysis.
Second, pronounced MR jet eccentricity may prohibit optimal alignment of the CW cursor, which led to the exclusion of 6% of subjects in the present study. If no optimal MR jet alignment can be obtained and/or if >10% of pixels within the CW envelope display a grayscale level of 255 au, we recommend not to use the API value for grading MR.
Third, the presence of multiple jets, each having at least moderate severity on color Doppler, limits the applicability of API, even for the PISA and VCW approach. Therefore, other echocardiographic methods for MR grading or CMR are to be considered in this situation. 5 Figure 5 MR quantification in nonholosystolic and holosystolic jets A representative nonholosystolic and holosystolic example of MVP-MR is shown in the left panels. The area of interest (the CW Doppler envelope) is converted to a grayscale format, and the envelope is manually traced to obtain the API value. In the middle panels, tracing of both envelopes is shown. In the right panels, the respective radii of the PISA flow convergence zones are shown. In the nonholosystolic MVP-MR example, the API value is relatively low (nonsevere MR), but the single-frame EROA calculation clearly suggests severe MR, whereas the time-corrected (using the TVI of the CW envelope) RV calculation indicates nonseverity of this nonholosystolic MVP-MR jet. Contrary to the API tracing approach, for obtaining the TVI value, the tracing of the CW envelope should be limited to the duration a MR, thus at the distinct CW envelope border.
Finally, as highlighted in the online API guide, variables other than the EROA or regurgitant blood volume (approximate number of scatterers) that may in theory affect the API value, such as speed/velocity of the regurgitation and turbulence, have been investigated previously, but controversial data were reported. 13, 14 Despite all these potential issues, a systemic misclassification of MR severity by API is unlikely, as the API method correlates significantly with direct and indirect measures of MR severity such as the PISA method, LV and LA dimensions, RVSP, and symptoms. 12, 15 A comprehensive overview of all theoretical considerations, the impact of machine settings, practical aspects, and potential limitations of the API method can be found in the online supplemental API guide.
In addition to the considerations on the API method, the present study also contains some limitations. For instance, the number of patients in our cohort and the number of events were moderate. Although the present development cohort study allowed us to determine an API severity cutoff for MVP-MR and ''optimization'' of the conventional PISA-EROA, PISA-RV, and VCW cutoffs, confirmation of the API cutoff in an independent validation cohort study may be required. Furthermore, we did not compare the API method in this study with a reference method such as three-dimensional echocardiography or CMR, because of the aforementioned limitations, and the present outcome data provide clinical validation of API. Finally, although this study provides evidence for clinical validation or proof of concept of the API method, multicenter studies are required for scalability testing and to strengthen our findings.
CONCLUSION
In the present study, we show that the API method is an echocardiographic MR grading parameter that is predictive of clinical events and outcomes in MVP-MR. The advantages make the API method a valuable tool for assessment and follow-up of MVP-MR in daily clinical practice.
